抗病毒治疗丙型肝炎肝硬化代偿期患者的临床疗效

Clinical efficacy of Antiviral Therapy in Hepatitis Cirrhosis Decompensation Period Patients

目的探讨抗病毒治疗丙型肝炎肝硬化代偿期患者的临床疗效。方法收集我院2012年6月至2014年6月丙型肝炎肝硬化代偿期146例患者资料,将患者按照随机数表法分为两组,各73例,A1组患者给予聚乙二醇干扰素a-2a+利巴韦林治疗,A2组患者给予常规保肝治疗。比较两组患者治疗12、24周后肝功能指标。结果两组患者治疗12周后,TBIL、ALT、AST以及HCV-RNA水平与治疗前比较,差异均无统计学意义(均P>0.05);治疗24周后,A1组患者TBIL、ALT、AST以及HCV-RNA水平明显优于A2组,差异均有统计学意义(均P<0.05)。结论聚乙二醇干扰素a-2a+利巴韦林治疗丙型肝炎肝硬化代偿期患者,针对病毒复制可表现出明显的抑制作用,患者的肝脏功能可获得明显改善,效果明显。

Objective To explore the clinical efficacy of antiviral therapy in hepatitis cirrhosis decompensation period patients.Methods Patients were colected in our hospital from 2012 June to 2014 data in June,hepatitis C cirrhosis 146 cases,according to the random number table method into two groups,each 73 cases,group A1 treated with pegylated interferon and ribavirin in the treatment of a-2a＋,A2 group was treated with routine treatment. Comparison of two groups of treatment of liver function index 12,24 weeks after.Results The patients in the two groups after 12 weeks treatment,the comparison of TBIL,ALT,AST and HCV-RNA levels and before treatment,no significant difference（P〉0.05）;after 24 weeks of treatment,patients in group A1 TBIL,ALT,AST and HCV-RNA levels were significantly better than those in A2 group,the difference was statisticaly significant（P〈0.05）.Conclusion Pegylated interferon a-2a＋ and ribavirin in the treatment of patients with hepatitis C cirrhosis,according to viral replication can be showed an obvious inhibition of liver function of patients can be improved evidently,the effect is obvious.